Cogent Biosciences has a Cash Ratio of 6.96. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Cogent Biosciences's Cash Ratio or its related term are showing as below:
COGT'
s Cash Ratio Range Over the Past 10 Years
Min: 2.82 Med: 7.4 Max: 18.5
Current: 6.96
During the past 9 years, Cogent Biosciences's highest Cash Ratio was 18.50. The lowest was 2.82. And the median was 7.40.
COGT's Cash Ratio is ranked better than 74.74% of 1524
companies
in the Biotechnology industry
Industry Median: 2.93
vs COGT: 6.96
Cogent Biosciences Cash Ratio Historical Data
The historical data trend for Cogent Biosciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cogent Biosciences's Cash Ratio
For the Biotechnology subindustry, Cogent Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Cash Ratio falls into.
Cogent Biosciences Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Cogent Biosciences's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (NAS:COGT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cogent Biosciences Cash Ratio Related Terms
Thank you for viewing the detailed overview of Cogent Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Cogent Biosciences (Cogent Biosciences) Business Description
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COGT has been successfully added to your 